Here, we found that both HSP70 inhibitor (VER-155008) or NAMPT inhibitor (FK886) and doxorubicin were able to repress MDA-MB-231 (containing p53 R280K mutation) breast cancer cell proliferation in a synergistic manner (Figure 5C,E). Here, NAMPT is linked to breast carcinoma.